Inside the research

Hims & Hers Health, Inc.

HIMS Research profile · latest available data

Price overview

$29.42

▲ +0.14 (+0.5%)

52w hi$62.76
52w lo$14.52
Vol8.19M
As of25 Sep 2026

The Verdict

Hold

Our score -0.36

Short-0.32
Medium-0.30
Long-0.53

computed 2026-09-27

Key fundamentals

Hims & Hers Health, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

Market cap$6.86B
Enterprise value$7.57B
Forward P/E39.90x
EV / EBITDA-743.76x
P / S (ttm)2.66x
Profit margin-5.5%
Return on equity-32.0%
Revenue growth+38.2%
Debt / equity477.13

Layer Breakdown

LayerRawContribution
Fundamental-0.04
Sector+0.08
Technical-0.27
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-09-27

Business overview

Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. The company was formerly known as Hims, Inc. and changed its name to Hims & Hers Health, Inc. in January 2021. The company was founded in 2017 and is based in San Francisco, California.

United States · www.hims.com

Risk Metrics

Beta vs SPX2.53
Corr SPX0.39
Annual vol104.0%
Annual ret+83.6%
Sharpe0.80
Max DD-78.9%

Window: 504 trading days (504 obs)

Material Events

DateEvent8-K
2026-08-10Earnings Release, Exhibitsread
2026-07-17Officer / Director Changeread
2026-07-01Material Agreement, Material Obligation…read
2026-06-15Shareholder Voteread
2026-06-02Material Agreement, Material Obligation…read
2026-05-21Material Agreement, Material Obligation…read
2026-05-19Other Material Event, Exhibitsread
2026-05-11Earnings Release, Exhibitsread
2026-03-11Reg FD Disclosure, Exhibitsread
2026-02-23Earnings Release, Exhibitsread
2026-02-19Material Agreement, Securities Issuance…read
2025-11-17Other Material Eventread

Flow & Concentration

Insider 180d net$0
Insider buys / sells0 / 0
Insider biasNeutral
13F holders8
Top-5 share99.2%
HHI2,814 (concentrated)

Top Holders

HolderValueShares
Citadel Advisors$348.06M10.04M
State Street Corp$282.41M8.15M
Fidelity / FMR LLC$149.89M4.32M
Capital Research / Capital World$101.22M2.92M
Millennium Management$23.22M669.60K
AQR Capital Management$7.07M210.08K
Bridgewater Associates$243.94K7.04K
T. Rowe Price Group$32.32K932.22K

As of 2026-06-30

SEC Filings

DateFormDoc
2026-08-144view
2026-08-144view
2026-08-144view
2026-08-144view
2026-08-144view
2026-08-144view
2026-08-144view
2026-08-144view
2026-08-144view
2026-08-144view
2026-08-1010-Qview
2026-08-108-Kview
2026-07-204view
2026-07-178-Kview
2026-07-074view

The Long Run

FY 2019–2025 · 7 years

LineLatestCAGRTrend
Revenue$2.35B+71.4%
Gross profit$1.73B+70.6%
Operating income$105.61M—
Net income$128.37M+11088.8%
Cash from ops$73.48M+0.0%

Indices

S&P MidCap 400

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$29.48$29.76$28.57$29.428.19M
Sep 24$28.00$29.65$27.31$29.2816.71M
Sep 23$30.40$30.95$28.32$28.3911.89M
Sep 22$29.95$31.81$29.22$30.4316.65M
Sep 21$28.50$29.52$28.18$29.358.45M

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →